pharmaphorum

FEBRUARY 9, 2022

In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. The oncology segment has been recognised as one of the most productive areas for pharmaceutical companies to focus their R&D investment.

Vaccines 133

Vaccines Immunization Compounding Pharmaceutical Companies 133

pharmaphorum

OCTOBER 21, 2022

The UK company reveals the results from a partner-led survey to discover the rates of vaccination for adults, why levels are lower than expected, and what can be done to improve this. The result of the improving knowledge of vaccines’ role in society initially led to a rise in interest in receiving a COVID-19 vaccine.

Vaccines 98

Vaccines Immunization Compounding Pharmaceutical Companies 98

pharmaphorum

AUGUST 27, 2020

Over the past five to ten years US investors have focused on technology and internet companies, and relatively little on new biotech or pharmaceutical companies. In the UK, structural problems of the AIM market have compounded these problems by driving institutional investors away from relatively illiquid shares.

Vaccines 117

Vaccines Compounding Pharmaceutical Companies Pharmaceutical Companies 117

Pharmaceutical Technology

APRIL 24, 2023

Demand for biologics, including vaccines, is at an all-time high, in the post-Covid era. There are fewer sites for cell and gene therapies and vaccines – 90 companies with 127 facilities, as per GlobalData figures. As a result, some pharmaceutical companies are turning to third parties.

Vaccines 52

Vaccines Compounding Pharmaceutical Companies Pharmaceutical Companies 52